1. Home
  2. ANAB vs OPEN Comparison

ANAB vs OPEN Comparison

Compare ANAB & OPEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ANAB
  • OPEN
  • Stock Information
  • Founded
  • ANAB 2005
  • OPEN 2014
  • Country
  • ANAB United States
  • OPEN United States
  • Employees
  • ANAB N/A
  • OPEN N/A
  • Industry
  • ANAB Biotechnology: Pharmaceutical Preparations
  • OPEN Real Estate
  • Sector
  • ANAB Health Care
  • OPEN Finance
  • Exchange
  • ANAB Nasdaq
  • OPEN Nasdaq
  • Market Cap
  • ANAB 759.5M
  • OPEN N/A
  • IPO Year
  • ANAB 2017
  • OPEN N/A
  • Fundamental
  • Price
  • ANAB $18.40
  • OPEN $1.01
  • Analyst Decision
  • ANAB Buy
  • OPEN Hold
  • Analyst Count
  • ANAB 10
  • OPEN 5
  • Target Price
  • ANAB $36.38
  • OPEN $1.70
  • AVG Volume (30 Days)
  • ANAB 907.9K
  • OPEN 42.2M
  • Earning Date
  • ANAB 05-08-2025
  • OPEN 05-01-2025
  • Dividend Yield
  • ANAB N/A
  • OPEN N/A
  • EPS Growth
  • ANAB N/A
  • OPEN N/A
  • EPS
  • ANAB N/A
  • OPEN N/A
  • Revenue
  • ANAB $91,280,000.00
  • OPEN $5,153,000,000.00
  • Revenue This Year
  • ANAB N/A
  • OPEN $4.11
  • Revenue Next Year
  • ANAB $59.43
  • OPEN $22.85
  • P/E Ratio
  • ANAB N/A
  • OPEN N/A
  • Revenue Growth
  • ANAB 432.03
  • OPEN N/A
  • 52 Week Low
  • ANAB $12.21
  • OPEN $0.96
  • 52 Week High
  • ANAB $41.31
  • OPEN $3.09
  • Technical
  • Relative Strength Index (RSI)
  • ANAB 55.72
  • OPEN 31.53
  • Support Level
  • ANAB $17.50
  • OPEN $1.15
  • Resistance Level
  • ANAB $19.60
  • OPEN $1.27
  • Average True Range (ATR)
  • ANAB 1.34
  • OPEN 0.08
  • MACD
  • ANAB 0.16
  • OPEN -0.01
  • Stochastic Oscillator
  • ANAB 57.04
  • OPEN 15.85

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: